Disclaimer
These statements are related, among others, to the intent, belief or current expectations of the customer base, estimates regarding future growth in the different business lines and the global business, market share, financial results and other aspects of the activities and situation relating to the Company. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and actual results may differ materially from those expressed in or implied by these forward-looking statements as a result of various factors, many of which are beyond the ability of DiaSorin S.p.A. to control or estimate precisely. The Company does not undertake to update or otherwise revise any forecasts or objectives presented herein, except in compliance with the disclosure obligations applicable to companies whose shares are listed on a stock exchange. Luigi De Angelis, the Officer Responsible for the preparation of corporate financial reports of DiaSorin S.p.A., in accordance with the second subsection of art. 154-bis, part IV, title III, second paragraph, section V-bis, of Legislative Decree February 24, 1998, no. 58, declares that, to the best of his knowledge, the financial information included in the present document corresponds to book of accounts and book-keeping entries of the Company.Â
2015-2017 PLAN:
STRATEGIC SETTING
Technology development
Y
AY D R E EST
Y A D R ESTE
Y
D INSTALLE ISON MENU OF LIA D CLIA IDATION THE BROA L CONSO WTH BASE, LEVERAGING D GRO BILITY AN H NC AVAILA NT, LAU E M P O DOM DEVEL L: D RAN ISON X AN A I L OF THE FITTING THROUGHPUT - HIGH INSTRUMENT LABS ACCESS MID-LARGE BLE OF AVAILA NEEDS CONTENT MENU - FULL tion plifica m a f o pment MP) Develo logy (Q-LA o IAM techn aison i L f n o h ractio nd launch t Launc x E f a o -how sition Acqui logy Know o techn on IXT is of Lia
W O R R O M TO
e ed bas l l a t s in aison i l f o nt son XL i a i L ageme f o Man nsion xpa E nuous se : Conti ba TIVITY C E ONN Installed L LAS C X ISON on LIA BUILD ships e - Alon gh partner u on XS - Thro s i a i L of pment o Devel ology Haemat Oncon i n iam on IXT s i Liaiso a i L ion of t a d i l E Conso ning MPLET O C A o i ith posit ing w n o i t i s rin po olution DiaSo s molecular
Technological full spectrum solution: from small to mega AUTOMATION CONNECTIVITY GA ME IG /B BS LA
STAND ALONE SOLUTION
E
IZ S ID
S
EASE OF USE
LAB
M
s
L
L A M
S
LAS
E Z I S
L
S AB
/
L PO
LIAISON速 XS
Liaison Xs: Strategic Positioning and pols in usa Small-size Labs / POLs < 200,000 Tubes / Year
Total Immunoassay market value of POLs in USA: > 300 $/mln
Accessible Immunoassay Market Value: > 260 $/mln
with low volumes, depending
12%
on the specific needs of
Low volumes
analysis with specialty and
Moderate volumes Ultra-low volumes
provide a reliable and efficient solution for CLIA tests in Labs
4%
High volumes
LIAISON XS is designed to
59%
routine tests
25%
LIAISON XS Total Market: > 115,000 POLs in USA
DIASORIN POSITIONING Tests/Year
~12,000-24,000
System Cost
~50% of Liaison XL
Reagents & consumables
Same of Liaison XL
Technical functioning and Software
Remote connectivity
Source: Company data
Accessible Market: 18,000 POLs in USA (CLIA certified)
Product Development
W O R R O M TO
Y A D R ESTE
D LTY AN A I C E P AS S
Y
LIDATION BY 2017 ET K CONSO E PLAYER: MAR ON THE ROUTIN CLIA TESTS 5 3 1 0 - 13 : ATION V MARKERS INNO ON EXISTING FOCUS USE OF - INNOVATIVE KERS MAR e v i vat - inno
E
CIALTY ON SPE
UTIN IGH RO H D AN
FOCUS : LEVERAGE ATEGY OFFER R T S TESTS THE E-TOO AND M TO EXPAND AND K OO H (e.g. HEPATITIS ON SPECIALTIES ROUTINE RKET TO HIGH ) HE MA T ON RETROVIRUS IA MENU EST CL BROAD TS) S (114 TE E
LITATIV
UA AND Q S E S A ISE IOUS D GY TESTS INFECT AEMATOLO H ONCOTESTS CTION EXTRA
HIGH
TESTS OLOGY T A M E CO-HA ON E V I ITAT QUANT TESTS CTION A R T X E
Innovative Use of Existing Markers & Innovative Markers
Clinical approach strategy to drive market expansion Prescribers, Regulators and Payers demand greater evidence of healthcare value Development of robust and sustained clinical program critical to commercial success
Innovative use of existing markers
Innovative markers
Practical examples
Innovative use of existing markers
Innovative markers
Chronic Kidney Diseases
Heart Failure
Vit D 1,25 PTH 1,84 Identification of Heart Failure Phase and Potential Outlook on its evolution
Phase
1
2
34
Sclerostin - a protein produced by our body that reduces the bone mass - ITS detection and quantitation in blood might have a diagnostic utility in high prevalence clinical conditions characterized by bone mass loss (e.g. postmenopausal osteoporosis and CKD)
FGF-23 Patients with Chronic Kidney Diseases requiring a prognostic test of deterioration of renal activity
Stage
1
2
34
680,000 Patients (in USA)
18 Million of Patients in CKD (in USA)
Intellectual Property
Intellectual Property
Sclerostin can bring to:
new clinical claims agreement with Pharma for companion diagnostic